This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
PRTK 株式概要
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
報酬
リスク分析
Paratek Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$2.23 |
| 52週高値 | US$3.65 |
| 52週安値 | US$1.29 |
| ベータ | 1.7 |
| 11ヶ月の変化 | 2.29% |
| 3ヶ月変化 | 0.91% |
| 1年変化 | -2.62% |
| 33年間の変化 | -60.95% |
| 5年間の変化 | -77.01% |
| IPOからの変化 | -86.06% |
最新ニュース
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06株主還元
| PRTK | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 2.3% | -0.1% | 0.5% |
| 1Y | -2.6% | 19.2% | 20.5% |
業界別リターン: PRTK underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
リターン対市場: PRTK underperformed the US Market which returned 13.8% over the past year.
価格変動
| PRTK volatility | |
|---|---|
| PRTK Average Weekly Movement | 1.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
安定した株価: PRTK has not had significant price volatility in the past 3 months.
時間の経過による変動: PRTK's weekly volatility has decreased from 13% to 2% over the past year.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1996 | 269 | Evan Loh | www.paratekpharma.com |
Paratek Pharmaceuticals, Inc. 基礎のまとめ
| PRTK 基礎統計学 | |
|---|---|
| 時価総額 | US$127.83m |
| 収益（TTM） | -US$62.73m |
| 売上高(TTM) | US$177.00m |
0.7x
P/Sレシオ-2.0x
PER（株価収益率PRTK は割高か？
公正価値と評価分析を参照収益と収入
| PRTK 損益計算書（TTM） | |
|---|---|
| 収益 | US$177.00m |
| 売上原価 | US$64.13m |
| 売上総利益 | US$112.87m |
| その他の費用 | US$175.60m |
| 収益 | -US$62.73m |
直近の収益報告
Jun 30, 2023
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.09 |
| グロス・マージン | 63.77% |
| 純利益率 | -35.44% |
| 有利子負債／自己資本比率 | -128.3% |
PRTK の長期的なパフォーマンスは？
過去の実績と比較を見る